- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
Quick take on Somatropin
Somatropin is recombinant human growth hormone (rhGH) — a synthetic version of the 191-amino acid protein that your pituitary gland produces naturally. First synthesized via recombinant DNA technology in 1981 by Genentech, replacing earlier cadaver-derived GH preparations (which carried fatal prion disease risk). Sold under dozens of brand names — Genotropin, Humatrope, Norditropin, Omnitrope, Saizen — and used medically for growth hormone deficiency in children and adults, Turner syndrome, chronic kidney disease in kids, AIDS-related wasting, and short bowel syndrome. The cornerstone of GH therapy for over 40 years.
Mechanism in plain English
Unlike secretagogues (Ipamorelin, Sermorelin) that tell your pituitary to release its own GH, somatropin is the hormone itself, injected directly. It binds to GH receptors throughout the body, directly stimulating tissues and triggering the liver to produce IGF-1, which does most of the downstream anabolic and regenerative work. The effect is much stronger than any secretagogue can produce, because you're bypassing the pituitary's regulatory limits entirely.
What it's used for
People take it for serious body recomposition (fat loss combined with lean tissue gain), accelerated recovery, improved sleep architecture, skin and connective tissue quality, and anti-aging applications. Effects are noticeable within 2-4 weeks (sleep and recovery first), with body composition changes developing over 3-6 months.
Upsides and downsides
Main upside — somatropin is the real deal and produces effects no secretagogue can match. Fat loss, particularly visceral fat reduction, is dramatic. Skin quality, joint comfort, recovery, and sleep improvements are consistent and substantial. For its approved medical indications, it's a genuinely life-changing treatment.
Main downside — the side effect list is meaningful: water retention and joint pain early in treatment, carpal tunnel syndrome, insulin resistance and elevated blood sugar, potential organomegaly with long-term high-dose use, and the long-standing concern about accelerated growth of existing cancers through IGF-1 elevation. Doses matter enormously — therapeutic doses rarely cause serious problems, while the high doses used in performance contexts dramatically increase risk.
Typical protocol
Therapeutic protocols run 1-3 IU per day subcutaneously for adult GH deficiency. Anti-aging protocols often use 1-2 IU daily. Performance and body composition protocols range 2-6 IU daily, cycled for months at a time. Most protocols split doses morning and pre-bed, or use single morning dosing to preserve natural nocturnal pulses.
Who should skip it
- Anyone with active cancer.
- Anyone with diabetic retinopathy.
- Anyone with severe obesity combined with sleep apnea.
- Anyone with uncontrolled diabetes.
- Anyone with a family history of hormone-sensitive cancers, given the IGF-1 elevation.
Regulatory status
Banned by WADA under category S2 — detectable through isoform ratio tests and biomarker panels. Legally prescribable for approved medical indications. Gray-market and generic versions from countries like China, India, and Turkey circulate widely, with associated purity and quality concerns.
In 1958, a Boston endocrinologist named Maurice Raben did something that would have been considered absurd a decade earlier. He extracted growth hormone from a human cadaver pituitary, purified it, and injected it into a child with severe growth hormone deficiency. The child started growing. It worked.
For the next 25 years, the only source of growth hormone was exactly this: cadaver pituitaries. Thousands of glands had to be harvested, pooled, and purified to produce enough hormone for a single patient's treatment. Supply was severely limited. Thousands of children with growth disorders went untreated because there wasn't enough hormone to go around.
Then in 1985, two events changed everything. First, cadaver-derived growth hormone was linked to Creutzfeldt-Jakob disease — a fatal prion disease that had been transmitted through contaminated pituitary extracts over a decade earlier. The product was immediately pulled from the market. Second, a small biotech company called Genentech got FDA approval for the first recombinant human growth hormone produced through bacterial expression of the cloned human gene [1]. The product was called Protropin, and it marked both a medical breakthrough and the birth of modern biotechnology.
Today, Somatropin — the generic name for all FDA-approved recombinant human growth hormone products — is one of the most consequential medications in endocrinology. It's saved countless children from growth failure, transformed adult growth hormone deficiency treatment, and become one of the most studied, most regulated, and most misused peptide drugs in history.
Somatropin: what it is and how it works in a nutshell
Somatropin is recombinant human growth hormone — a 191-amino-acid single-chain polypeptide that is biochemically identical (or near-identical) to the growth hormone naturally produced by your pituitary gland. The only structural differences between brand products and natural GH are trivial variations in manufacturing (some products add a methionine residue used in bacterial expression).
Production: Made by inserting the human GH gene into bacteria (E. coli) or mammalian cells (CHO cells), which then produce the hormone at industrial scale. This is the original "biotech drug" — the success of recombinant somatropin proved the platform that later enabled insulin, interferons, monoclonal antibodies, and most modern biologics.
FDA-approved brand names in the US:
- Genotropin (Pfizer)
- Humatrope (Eli Lilly)
- Norditropin (Novo Nordisk) — first approved 1987
- Nutropin and Nutropin AQ (Genentech)
- Omnitrope (Sandoz) — first FDA-approved biosimilar growth hormone (2006)
- Saizen (Merck Serono)
- Zomacton / Tev-Tropin (Teva)
- Serostim (EMD Serono) — specifically approved for HIV wasting
- Skytrofa (Ascendis) — long-acting pegylated somatropin
- Sogroya (Novo Nordisk) — once-weekly somapacitan
All are prescription-only, Schedule III-regulated in many states, and carry significant regulatory oversight. Somatropin is not a research peptide or off-label compound — it's a fully-approved pharmaceutical with decades of clinical data.
Somatropin mechanism of action: what it actually does in the body
Unlike the GHRH analogs covered elsewhere on this blog (Sermorelin, Mod GRF 1-29, CJC-1295), Somatropin is the actual growth hormone itself. You're not asking your pituitary to produce more — you're bypassing the pituitary entirely and supplying the hormone directly.
The receptor and signaling:
- Subcutaneous injection → Somatropin enters circulation
- Binds the growth hormone receptor (GHR) — a cytokine receptor family member present on most tissues
- JAK2-STAT5 signaling cascade activation
- IGF-1 production stimulated primarily in the liver (but also locally in tissues)
- Direct effects on fat metabolism, protein synthesis, and glucose metabolism
- Indirect effects via elevated IGF-1 on cell growth, tissue repair, and anabolism
What it actually does physiologically:
- Stimulates linear growth in children with open epiphyses (growth plates)
- Increases muscle mass and reduces fat mass (particularly visceral fat)
- Stimulates protein synthesis throughout tissues
- Mobilizes fat for energy (lipolysis in adipose tissue)
- Increases glucose production (counter-regulatory to insulin)
- Stimulates bone turnover and improves bone mineral density
- Modulates immune function (thymic effects, lymphocyte development)
The critical distinction from GHRH analogs: GHRH analogs ask your pituitary to release YOUR OWN GH in your natural pulsatile pattern with feedback intact. Somatropin provides exogenous GH directly, producing supraphysiological peak levels, non-pulsatile exposure, suppression of endogenous production, faster and stronger effects — and a higher side effect profile proportional to the stronger effect.
Pharmacokinetics: Plasma half-life is approximately 21-25 minutes when given IV. Subcutaneous injection produces peak levels at 4-5 hours and more gradual decline. Despite the short half-life, biological effects last much longer because downstream IGF-1 elevation persists for 24+ hours after injection.
Who uses Somatropin and what for
FDA-approved pediatric indications:
- Growth hormone deficiency (GHD) in children — the original indication. Still the most common use.
- Turner syndrome — girls with a missing or abnormal X chromosome, causing short stature
- Noonan syndrome — genetic disorder with short stature and other features
- Prader-Willi syndrome — approved for children with this genetic disorder
- Small for gestational age (SGA) without catch-up growth — children born small who don't catch up by age 2
- SHOX gene deficiency — genetic cause of short stature
- Idiopathic short stature (ISS) — FDA-approved 2003 for children below -2.25 standard deviations who aren't expected to reach normal adult height
- Chronic renal insufficiency — children with growth failure from kidney disease
FDA-approved adult indications:
- Adult GHD (AGHD) — adults with confirmed GH deficiency from pituitary disease, surgery, radiation, or trauma
- HIV-associated wasting — the Serostim indication specifically
- Short bowel syndrome — Zorbtive approved for this rare condition
Off-label uses (with varying legitimacy):
- Age-related GH decline — the most controversial use. Not FDA-approved. The DEA has taken the position that off-label prescribing of HGH for anti-aging is illegal under federal law, though enforcement has been inconsistent [2].
- Sports performance enhancement — prohibited by every major sports body and WADA. Illegal for this purpose.
- Bodybuilding — widely practiced in competitive bodybuilding, illegal for this use.
Realistic expectations for properly-diagnosed adult GHD on physiological replacement doses: improved body composition (reduced visceral fat, increased lean mass), better bone mineral density over years of treatment, improved energy and quality of life, reduced cardiovascular risk factors, improved exercise capacity, modest strength gains.
What Somatropin stacks with in medical contexts
In properly-supervised clinical contexts:
- Somatropin + Testosterone — for men with both GHD and hypogonadism, these are often replaced together
- Somatropin + Thyroid hormone — GHD often coexists with other pituitary hormone deficiencies; replacement of all deficient hormones is standard
- Somatropin + Cortisol replacement — for panhypopituitarism
Important framing: Somatropin is fundamentally different from GHRH peptides in the stacking conversation. GHRH peptides amplify your natural pulsatile GH. Somatropin replaces or overrides the whole system. Combining them doesn't produce synergy — it produces redundancy with feedback suppression.
Somatropin side effects and risks
Because Somatropin has been used in millions of patients for decades, its side effect profile is extensively characterized. The severity scales with dose — physiological replacement in GHD patients produces very different risk profile than supraphysiological bodybuilding doses.
Common side effects at physiological doses:
- Fluid retention — swelling in hands and feet, particularly early in treatment
- Arthralgia and myalgia — joint and muscle pain, common in first few weeks
- Injection site reactions — redness, small bumps
- Headache — particularly in first month
- Mild carpal tunnel symptoms — tingling in hands, resolves with dose adjustment
- Peripheral edema
Side effects more pronounced at higher doses:
- Significant carpal tunnel syndrome — can require surgical intervention
- Severe fluid retention
- Insulin resistance and glucose intolerance — can unmask or worsen diabetes
- Acromegaly-like features — enlarged hands, feet, jaw, facial features with chronic high doses
- Joint pain and cartilage issues
- Sleep apnea — new onset or worsening
- Hypertension
Serious risks (FDA labeling):
- Intracranial hypertension — rare but serious, particularly in pediatric patients
- Slipped capital femoral epiphysis — hip problems in rapidly growing children
- Worsening scoliosis — in children with existing scoliosis
- Pancreatitis — rare
- Increased mortality — the 2010 SAGhE study reported increased mortality in French patients treated with GH during childhood compared to general population. FDA has reviewed and concluded benefits still outweigh risks for approved indications, but the finding added caution to long-term use [3].
Cancer concerns. GH/IGF-1 axis activation has theoretical cancer concerns. Clinical data is mixed and context-dependent. GHD patients being replaced to normal levels don't show clear increased cancer risk; supraphysiological use in otherwise healthy adults remains theoretically concerning without large-scale long-term data.
Who should absolutely avoid:
- Anyone with active cancer (other than specific situations)
- Active diabetic retinopathy
- Critical illness with acute respiratory failure
- Prader-Willi patients who are severely obese or have severe respiratory impairment
- Pregnant or breastfeeding women
- Children with closed growth plates (epiphyses fused)
The legal framing matters. In the United States, distributing human growth hormone for any purpose other than an FDA-approved indication through a physician's legitimate medical practice is a federal crime under 21 USC 333(e). This applies to bodybuilding, anti-aging, and performance use. Legitimate medical use under proper diagnosis is legal; off-label distribution is not.
How to use and store Somatropin
All somatropin products are prescription-only. Typical medical protocols:
- Pediatric GHD: 0.024-0.034 mg/kg/day, 6-7 days per week, subcutaneous injection
- Adult GHD: starting at 0.2 mg/day, titrated to achieve IGF-1 levels in upper normal range (typically 0.3-0.6 mg/day maintenance)
- Cycle: continuous therapy for confirmed deficiencies; there's no "cycling" in proper medical use
Injection technique: subcutaneous in abdomen, thigh, or upper arm. Rotate sites. Most products come in prefilled pens or cartridges for convenience.
Storage: refrigerated at 2-8°C. Some products can be kept at room temperature briefly after first use. Do not freeze. Follow specific product labeling — storage requirements vary significantly between brands.
Labs and monitoring during Somatropin therapy
More extensive than any other peptide covered on this blog because the effects are larger and the risks are real.
Before starting: formal diagnosis of GHD through provocative testing (insulin tolerance test, glucagon stimulation, or similar), baseline IGF-1, fasting glucose, HbA1c, thyroid function, full pituitary workup if indicated, DXA for bone density, ophthalmology exam (retinopathy screening), cardiovascular assessment.
During therapy: IGF-1 every 6-8 weeks during titration, then every 6 months. Target: IGF-1 in upper half of normal range for age. Also monitor: fasting glucose, HbA1c, thyroid function, lipids, blood pressure, body composition, quality of life measures.
Long-term monitoring: annual ophthalmology exams, periodic cardiovascular assessment, cancer screening appropriate for age.
Somatropin vs alternatives: what's different
- GHRH analogs (Sermorelin, Mod GRF 1-29, CJC-1295) — stimulate natural GH production. Gentler, more physiological, preserve feedback. Much milder effects. Better choice for people with intact pituitary function seeking optimization rather than replacement.
- GHRPs (Ipamorelin, GHRP-2) — ghrelin receptor agonists, different pathway. Usually stacked with GHRH analogs.
- Tesamorelin — FDA-approved GHRH analog for HIV lipodystrophy. More targeted effect on visceral fat than somatropin in that specific population.
- IGF-1 LR3 — the downstream product of GH. Direct IGF-1 administration, different risk profile.
- GLP-1 agonists (semaglutide, tirzepatide) — completely different mechanism. For weight loss, FDA-approved alternatives with better risk-benefit profile than off-label somatropin.
Somatropin's distinguishing feature: the actual growth hormone, supplying what the body would naturally make — with all the benefits and all the risks of supraphysiological dosing when used beyond replacement. For genuine GHD, it's the definitive treatment. For anti-aging and performance use, it's a controlled substance with significant legal and medical risks.
Myths about Somatropin
- "HGH is the fountain of youth." The famous 1990 Rudman study showing improved body composition in elderly men from HGH gets cited endlessly, but it was a small short-term study, subsequent research has shown the side effect burden at anti-aging doses is significant, and no large long-term trial has confirmed meaningful longevity benefits. Actual anti-aging effect is modest at safe doses; at doses large enough to produce dramatic changes, side effects and cancer risk concerns become real issues.
- "Somatropin and Sermorelin do the same thing." They don't. Somatropin is the hormone itself at potentially supraphysiological levels with feedback suppression. Sermorelin stimulates your natural pituitary in physiological pulses with feedback intact. For confirmed GHD, somatropin is more effective. For healthy adults pursuing optimization, sermorelin (or its longer-acting analogs) is generally safer and legally clearer.
Sources
- U.S. Food and Drug Administration. Somatropin Information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/somatropin-information — official FDA information on approved indications and safety.
- Perls, T. T., Reisman, N. R., & Olshansky, S. J. (2005). Provision or distribution of growth hormone for "antiaging": clinical and legal issues. JAMA, 294(16), 2086-2090. — foundational paper on legal issues around off-label HGH distribution in the US.
- Carel, J. C., Ecosse, E., Landier, F., Meguellati-Hakkas, D., Kaguelidou, F., Rey, G., & Coste, J. (2012). Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. Journal of Clinical Endocrinology & Metabolism, 97(2), 416-425. — the SAGhE study that raised mortality concerns.
- U.S. Food and Drug Administration. FDA Drug Safety Communication: Ongoing safety review of Recombinant Human Growth Hormone (somatropin) and possible increased risk of death. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-ongoing-safety-review-recombinant-human-growth-hormone-somatropin-and — FDA response to the SAGhE findings.
- Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., Vance, M. L., & Endocrine Society. (2011). Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 96(6), 1587-1609. — authoritative clinical guidelines for adult GHD treatment.
- Grimberg, A., DiVall, S. A., Polychronakos, C., Allen, D. B., Cohen, L. E., Quintos, J. B., Rossi, W. C., Feudtner, C., & Murad, M. H. (2016). Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents. Hormone Research in Paediatrics, 86(6), 361-397. — pediatric clinical guidelines.
- Rudman, D., Feller, A. G., Nagraj, H. S., Gergans, G. A., Lalitha, P. Y., Goldberg, A. F., Schlenker, R. A., Cohn, L., Rudman, I. W., & Mattson, D. E. (1990). Effects of human growth hormone in men over 60 years old. New England Journal of Medicine, 323(1), 1-6. — the famous paper that launched off-label anti-aging HGH use (and has been widely misinterpreted in subsequent popular discussion).
- World Anti-Doping Agency (WADA). Prohibited List — Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. https://www.wada-ama.org — Somatropin classification in competitive sport.
Somatropin Dosage Guide
Somatropin is recombinant human growth hormone (rhGH), a 191-amino-acid protein with an identical structure to endogenous pituitary GH, produced via recombinant DNA technology since 1987. It binds the growth hormone receptor throughout the body to stimulate hepatic IGF-1 production, increase protein synthesis, drive lipolysis, and promote cellular growth and tissue repair. Unlike GHRH analogs (Sermorelin, CJC-1295), it delivers preformed GH directly into circulation, bypassing the pituitary and creating supraphysiological peaks rather than pulsatile secretion. This guide is aimed at adults with diagnosed growth hormone deficiency (AGHD), users exploring anti-aging and body composition protocols under medical supervision, and athletes pursuing recovery and hypertrophy benefits. Dosing below combines the FDA-approved prescribing information for Genotropin, Norditropin, Humatrope, Saizen, and Omnitrope, the Endocrine Society AGHD guidelines, and the off-label performance protocols that have emerged — though bodybuilding doses are not FDA-approved and carry significant risk.
Real-World Dosage Protocols by Experience Level
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Clinical starter (AGHD) | 0.15–0.3 mg (~0.5–1 IU) | Once daily, SC pre-bed | Titrate by 0.1–0.2 mg every 1–2 months |
| Anti-aging (conservative) | 1 IU (~0.33 mg) | Once daily, SC pre-bed | Well-tolerated, few side effects |
| Anti-aging (standard) | 2 IU (~0.67 mg) | Once daily, SC pre-bed | Commonly cited "sweet spot" |
| Fat loss / recomposition | 3–4 IU (~1.0–1.33 mg) | Once daily or split AM/pre-workout | Side effects more common |
| Performance (advanced, off-label) | 4–8 IU (~1.33–2.67 mg) | Split 2x daily, SC | Significant water retention, insulin resistance |
| Advanced bodybuilding (off-label) | 8–15 IU | Split 2x daily, SC | High risk; not medically recommended |
Doses also shift depending on the specific goal. The same hormone used for medical GH replacement versus athletic enhancement follows dramatically different protocols with correspondingly different risk profiles.
Dosage by Goal
| Goal | Recommended Dose | Frequency | Cycle Length |
|---|---|---|---|
| Adult GHD replacement (clinical) | 0.2–0.4 mg | Once daily, SC pre-bed | Ongoing, IGF-1 guided |
| Anti-aging / general wellness | 1–2 IU | Once daily, SC pre-bed | 3–6 months / 1 month off |
| Skin, sleep, recovery | 1–2 IU | Once daily, SC pre-bed | 3–6 months |
| Fat loss | 2–4 IU | Once daily AM fasted, SC | 12–16 weeks |
| Muscle gain / performance | 4–6 IU | Split AM + pre-workout, SC | 16–24 weeks |
| Post-cycle / recovery adjunct | 2 IU | Once daily, SC pre-bed | 6–12 weeks |
| Stacked with testosterone | 2–4 IU | Once daily, SC pre-bed | Aligned with TRT |
Inject pre-bed or split AM + pre-workout on an empty stomach (fasted) — insulin and GH have antagonistic effects on fat storage, so dosing away from meals maximizes lipolysis and IGF-1 conversion. Titrate slowly from a low starting dose; most dose-related side effects (water retention, carpal tunnel, joint pain, facial swelling) arise within the first months and either subside with adaptation or require dose reduction. Monitor IGF-1 at baseline and every 6–8 weeks — aim for mid-normal range for age and sex, as supraphysiological IGF-1 levels (the "HGH gut" visceral growth, insulin resistance, and potential cancer risk) come from pushing beyond this range. Absolute contraindications include active malignancy, diabetic retinopathy, critical illness (post-surgery, trauma, respiratory failure), Prader-Willi with severe obesity or airway obstruction, and pregnancy — and somatropin consistently reduces insulin sensitivity, so pre-diabetics and diabetics need close glucose monitoring.
Somatropin Storage Guide: How to Keep Your Medication Stable and Effective
Somatropin (recombinant human growth hormone) ships as a sterile white lyophilized powder in a sealed vial or two-chamber cartridge, freeze-dried to preserve this 191-amino-acid protein and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition until the expiration date printed on the label. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Refrigerated at 2–8°C (36–46°F) until the printed expiration date, typically 18–36 months from manufacture. A few formulations (such as Serostim) are shipped stable at controlled room temperature — always check the product label. | Keep in the main body of the fridge, not the door, to avoid temperature swings. |
| Light Sensitivity | Yes — protect from direct light to prevent protein degradation. | Keep the vial in its original carton or box until ready to reconstitute. |
| Freezing | Not allowed. Freezing damages the protein's folded structure and permanently reduces potency for most somatropin formulations. | If a vial freezes accidentally, discard it — do not thaw and use. |
| Signs of Degradation | Healthy powder is white, dry, and loose or cake-like. Watch for yellowing, browning, clumping, visible moisture, or a sticky texture. | Any color change, clumping, or moisture = discard the vial. |
| Common Mistakes | Storing in the fridge door where temperature fluctuates, placing near the freezer compartment, leaving out at room temperature, or keeping in a humid bathroom cabinet. | Keep it on a stable interior shelf in the fridge, and let it warm ~30 minutes at room temperature before use. |
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 4–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 13–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
Somatropin is a synthetic, recombinant form of human growth hormone (HGH) — it is identical in amino acid sequence to the growth hormone your pituitary gland naturally produces. It is made using recombinant DNA technology in genetically modified bacteria (usually E. coli). Somatropin is FDA-approved and sold under several brand names, including Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton, Serostim, and Zorbtive. It has been used as prescription therapy since 1987 and is administered by subcutaneous injection.
Somatropin works exactly like your body's natural growth hormone. It binds to growth hormone receptors on cells throughout the body, triggering a cascade of effects: stimulating protein synthesis, promoting bone and tissue growth, increasing fat breakdown (lipolysis), and raising blood glucose. Most of its growth-promoting effects are actually mediated by insulin-like growth factor 1 (IGF-1), which the liver produces in response to GH stimulation. Because somatropin replaces what the pituitary should be making, it bypasses natural feedback control — meaning dose control by the prescribing clinician is critical.
Somatropin is FDA-approved for several legitimate medical conditions. In children: growth hormone deficiency, Turner syndrome, Noonan syndrome, Prader-Willi syndrome, chronic kidney disease, short stature homeobox (SHOX) deficiency, idiopathic short stature, and small-for-gestational-age with no catch-up growth. In adults: growth hormone deficiency (from pituitary tumors, surgery, or trauma), HIV-associated wasting syndrome (Serostim), and short bowel syndrome (Zorbtive). It is not FDA-approved for anti-aging, bodybuilding, or athletic enhancement — though it's widely used off-label for those purposes.
Dosing varies enormously by indication, age, and brand. For pediatric GH deficiency, typical doses are 0.024 to 0.034 mg/kg daily, injected 6–7 times per week. For adult GH deficiency, doses start low (around 0.2 mg/day) and titrate up based on IGF-1 blood levels, usually ending between 0.2 and 1.0 mg daily. Older adults typically need lower doses. Somatropin is almost always administered subcutaneously in the evening to mimic natural overnight GH release. Dosing should always be set and monitored by an endocrinologist or qualified physician.
The most common side effects are fluid retention (swelling of the hands and feet), joint and muscle pain, carpal tunnel syndrome, headache, numbness or tingling, and injection-site reactions. More serious side effects include insulin resistance and new-onset type 2 diabetes, pancreatitis, increased intracranial pressure, worsening of scoliosis in children, and, rarely, allergic reactions. Long-term safety concerns include possible increased cancer risk, though evidence is mixed. The French SAGhE study raised concerns about increased mortality in adults treated with GH as children, prompting ongoing FDA review.
Yes, somatropin and HGH (human growth hormone) are essentially the same thing — somatropin is the official pharmaceutical name for recombinant human growth hormone that has the same 191-amino-acid sequence as natural pituitary-produced HGH. "HGH" is the more general term. There is a separate, older, now-rarely-used recombinant form called somatrem (brand name Protropin), which had an extra methionine at the N-terminus and is no longer commonly produced. Modern GH therapy is virtually all somatropin.
This is controversial. While growth hormone declines naturally with age (somatopause), the evidence that supplementing GH in older adults produces meaningful anti-aging benefits is limited, and the risks are real. A well-known 1990 study suggested modest improvements in body composition, but follow-up research has shown that the risks — insulin resistance, edema, carpal tunnel, and possibly increased cancer risk — outweigh benefits in healthy adults. Somatropin is not FDA-approved for anti-aging, and US federal law specifically prohibits prescribing it for this purpose (21 U.S.C. §333(e)). Legitimate anti-aging clinicians generally prefer GH-releasing peptides like Sermorelin instead.
Somatropin is contraindicated in people with active cancer or a history of malignancy, active severe illness (complications from open heart or abdominal surgery, trauma, respiratory failure), proliferative or severe non-proliferative diabetic retinopathy, closed epiphyses (growth plates) in children being treated for short stature, and Prader-Willi syndrome patients with severe obesity or respiratory impairment. Pregnant and breastfeeding women should not use it. Anyone with diabetes, intracranial hypertension, or scoliosis needs careful monitoring during treatment.
Somatropin is expensive. In the US, retail prices typically run $500 to $3,000 per month depending on brand and dose, with some long-acting formulations (like Skytrofa, a weekly injection) costing considerably more. Insurance coverage varies widely — pediatric GH deficiency is often covered, while adult GH deficiency coverage can be more difficult to obtain and requires documented pituitary testing. Off-label use for anti-aging or bodybuilding is virtually never covered by insurance, pushing many users toward black-market or counterfeit sources, which pose significant safety risks.
Somatropin is a prescription-only medication and fully legal in the US when prescribed by a physician for an FDA-approved indication. US law specifically criminalizes distributing or prescribing HGH for purposes other than an approved medical indication — non-medical use is a federal offense. Somatropin is on the WADA prohibited list, so athletes face sanctions for use. A significant black market exists, and counterfeit HGH is a major problem globally — products sold as "HGH" online are frequently underdosed, contaminated, or contain entirely different substances.
